Kazia Therapeutics (KZIA) Liabilities from Discontinued Operations (2024)
Kazia Therapeutics (KZIA) posted Liabilities from Discontinued Operations of 2489967.87 for Q4 2024, up 62.28% on a QoQ basis from 6601947.15 in Q2 2024.
Kazia Therapeutics (KZIA) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 2489967.87 in Q4 2024.
- In Q4 2024, Liabilities from Discontinued Operations changed N/A year-over-year to 2489967.87; the TTM figure through Dec 2024 stood at 2489967.87 (changed N/A YoY), while the FY2024 annual figure was 6601947.15, changed N/A from the prior year.
- Liabilities from Discontinued Operations improved to 2489967.87 in Q4 2024, from 6601947.15 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 2489967.87 in Q4 2024 and bottomed at 6601947.15 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kazia Therapeutics | 1.55 Bn | 1.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.49 Mn |
| Dec 31, 2024 | -2.49 Mn |
| Jun 30, 2024 | -6.60 Mn |
| Jun 30, 2024 | -6.60 Mn |